Fig. 2
From: Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive urothelial carcinoma
Trends in perioperative therapy use. (A) Trends in the use of neoadjuvant and adjuvant therapies in all patients with MIBC or UTUC. (B) Trends in the use of adjuvant therapies in patients with pathological high-risk disease. (C) Comparison of adjuvant therapy use in patients with pathological high-risk disease before 2022 and after 2022. (D) Trends in the use of adjuvant therapies (chemotherapy or immunotherapy) in patients with pathological high-risk disease. (E) Comparison of the type of adjuvant therapy in patients with pathological high-risk disease before 2022 and after 2022. (F) Differences in the rate of NAC use between adjuvant chemotherapy and immunotherapy.
